Tags

Type your tag names separated by a space and hit enter

Differential expression of pro-inflammatory cytokines in intra-epithelial T cells between trachea and bronchi distinguishes severity of COPD.
Cytokine. 2012 Dec; 60(3):843-8.C

Abstract

Measuring T-cell production of intracellular cytokines by flow cytometry enables specific monitoring of airway inflammation and response to therapies in chronic lung diseases including chronic obstructive pulmonary disease (COPD). We have previously shown that T cells in the airways of ex- and current- smoker COPD patients and healthy smokers produce increased T-cell pro-inflammatory cytokines IFNγ and TNFα versus healthy controls. However, we could not differentiate between COPD groups and smokers due to a high degree of inter-patient variability. To address this limitation, we hypothesized that intraepithelial T cells obtained from brushings of trachea may serve as an ideal intra-patient control compared with cells obtained from left and right bronchi. Production of intracellular cytokines by intraepithelial T-cells obtained from trachea and right and left bronchi from 26 individuals with COPD (16 with GOLD I and 10 with GOLD II-III disease), 11 healthy controls and 8 smokers was measured by flow cytometry. There was a significant increase in intraepithelial T-cell IFNγ and TNFα in both right and left bronchi of GOLD II-III COPD patients compared to cells obtained from the trachea. There were no changes in T cell pro-inflammatory cytokines between the bronchi and trachea from control subjects, GOLD I COPD patients or healthy smokers. There was a significant negative correlation between increased intraepithelial IFNγ and TNFα in bronchial brushing T-cells compared with tracheal T-cells, and compared with FEV1. Monitoring intracellular intra-epithelial T-cell cytokine production in bronchial brushings using autologous tracheal brushings as controls provides improves the sensitivity of the technique. Therapeutic targeting of these pro-inflammatory cytokines and assessing the effects of drugs on immune reactivity has the potential to reduce lung inflammation caused by intra-epithelial T cells in COPD.

Authors+Show Affiliations

Lung Research, Hanson Institute, Royal Adelaide Hospital, Adelaide, SA 5001, Australia. greg.hodge@health.sa.gov.auNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22929410

Citation

Hodge, Greg, et al. "Differential Expression of Pro-inflammatory Cytokines in Intra-epithelial T Cells Between Trachea and Bronchi Distinguishes Severity of COPD." Cytokine, vol. 60, no. 3, 2012, pp. 843-8.
Hodge G, Reynolds PN, Holmes M, et al. Differential expression of pro-inflammatory cytokines in intra-epithelial T cells between trachea and bronchi distinguishes severity of COPD. Cytokine. 2012;60(3):843-8.
Hodge, G., Reynolds, P. N., Holmes, M., & Hodge, S. (2012). Differential expression of pro-inflammatory cytokines in intra-epithelial T cells between trachea and bronchi distinguishes severity of COPD. Cytokine, 60(3), 843-8. https://doi.org/10.1016/j.cyto.2012.07.022
Hodge G, et al. Differential Expression of Pro-inflammatory Cytokines in Intra-epithelial T Cells Between Trachea and Bronchi Distinguishes Severity of COPD. Cytokine. 2012;60(3):843-8. PubMed PMID: 22929410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential expression of pro-inflammatory cytokines in intra-epithelial T cells between trachea and bronchi distinguishes severity of COPD. AU - Hodge,Greg, AU - Reynolds,Paul N, AU - Holmes,Mark, AU - Hodge,Sandra, Y1 - 2012/08/25/ PY - 2012/05/14/received PY - 2012/07/16/revised PY - 2012/07/17/accepted PY - 2012/8/30/entrez PY - 2012/8/30/pubmed PY - 2013/5/15/medline SP - 843 EP - 8 JF - Cytokine JO - Cytokine VL - 60 IS - 3 N2 - Measuring T-cell production of intracellular cytokines by flow cytometry enables specific monitoring of airway inflammation and response to therapies in chronic lung diseases including chronic obstructive pulmonary disease (COPD). We have previously shown that T cells in the airways of ex- and current- smoker COPD patients and healthy smokers produce increased T-cell pro-inflammatory cytokines IFNγ and TNFα versus healthy controls. However, we could not differentiate between COPD groups and smokers due to a high degree of inter-patient variability. To address this limitation, we hypothesized that intraepithelial T cells obtained from brushings of trachea may serve as an ideal intra-patient control compared with cells obtained from left and right bronchi. Production of intracellular cytokines by intraepithelial T-cells obtained from trachea and right and left bronchi from 26 individuals with COPD (16 with GOLD I and 10 with GOLD II-III disease), 11 healthy controls and 8 smokers was measured by flow cytometry. There was a significant increase in intraepithelial T-cell IFNγ and TNFα in both right and left bronchi of GOLD II-III COPD patients compared to cells obtained from the trachea. There were no changes in T cell pro-inflammatory cytokines between the bronchi and trachea from control subjects, GOLD I COPD patients or healthy smokers. There was a significant negative correlation between increased intraepithelial IFNγ and TNFα in bronchial brushing T-cells compared with tracheal T-cells, and compared with FEV1. Monitoring intracellular intra-epithelial T-cell cytokine production in bronchial brushings using autologous tracheal brushings as controls provides improves the sensitivity of the technique. Therapeutic targeting of these pro-inflammatory cytokines and assessing the effects of drugs on immune reactivity has the potential to reduce lung inflammation caused by intra-epithelial T cells in COPD. SN - 1096-0023 UR - https://www.unboundmedicine.com/medline/citation/22929410/Differential_expression_of_pro_inflammatory_cytokines_in_intra_epithelial_T_cells_between_trachea_and_bronchi_distinguishes_severity_of_COPD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-4666(12)00604-7 DB - PRIME DP - Unbound Medicine ER -